| Adolfo Sanchez Ortiz, MD | |
|
Antonio R. Barcelo # 5, Cayey, PR 00736 | |
| (787) 738-7595 | |
| (787) 738-7595 |
| Full Name | Adolfo Sanchez Ortiz |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 40 Years |
| Location | Antonio R. Barcelo # 5, Cayey, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821017419 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 8955 (Puerto Rico) | Primary |
| Entity Name | Cardivascular Amb Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871653543 PECOS PAC ID: 9931268935 Enrollment ID: O20081105000696 |
News Archive
The idea of team-based cancer care most often focuses on involving primary care physicians in the care of cancer survivors. But research has shown patients are discussing initial cancer treatment options with their primary care doctors.
Supernus Pharmaceuticals, Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN812 for the treatment of ADHD in adults. The trial is a proof-of-concept, randomized, double-blind, placebo-controlled study in healthy adults aged 18 to 64, inclusive, with ADHD. Supernus expects to enroll 50 subjects in the study at 5 sites across the United States.
OncoGenex Pharmaceuticals, Inc. today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various solid tumors. Patients enrolled had a diagnosis of castrate resistant prostate cancer, breast cancer, ovarian cancer or non-small cell lung cancer.
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
The secret to the ability of a molecule critical for cell division to throw off the protein yoke that restrains its activity is the yoke itself - a disorderly molecule that seems to have a mind of its own, say investigators at St. Jude
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adolfo Sanchez Ortiz, MD Perla Del Caribe 205, Mansiones Monte Verde, Cayey, PR 00736 Ph: (787) 738-7595 | Adolfo Sanchez Ortiz, MD Antonio R. Barcelo # 5, Cayey, PR 00736 Ph: (787) 738-7595 |
News Archive
The idea of team-based cancer care most often focuses on involving primary care physicians in the care of cancer survivors. But research has shown patients are discussing initial cancer treatment options with their primary care doctors.
Supernus Pharmaceuticals, Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN812 for the treatment of ADHD in adults. The trial is a proof-of-concept, randomized, double-blind, placebo-controlled study in healthy adults aged 18 to 64, inclusive, with ADHD. Supernus expects to enroll 50 subjects in the study at 5 sites across the United States.
OncoGenex Pharmaceuticals, Inc. today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various solid tumors. Patients enrolled had a diagnosis of castrate resistant prostate cancer, breast cancer, ovarian cancer or non-small cell lung cancer.
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
The secret to the ability of a molecule critical for cell division to throw off the protein yoke that restrains its activity is the yoke itself - a disorderly molecule that seems to have a mind of its own, say investigators at St. Jude
› Verified 8 days ago
Mirelis M Fabian Argueta, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Carr 14 Km 72.0 Bo Rincon Sec Lomas, Hospital Menonita Cayey, Cayey, PR 00737 Phone: 787-535-1001 Fax: 787-535-1012 | |
Biomaris Medina-rivera, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Road 14 Km. 72.2 Bo. Rincon Sector Lomas, Cayey, PR 00737 Phone: 787-535-1001 Fax: 787-535-1012 | |
Dr. Eric David Aviles, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Edificio Profesional Hospital Menonite, Suite # 207, Cayey, PR 00973 Phone: 787-738-2200 | |
Omayra Reyes Santiago, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Carr 14 Km 71.9, Int Bo Montellano, Cayey, PR 00736 Phone: 787-520-7211 Fax: 787-520-7212 | |
Dr. Jose M. Marcial Suarez, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Centro Medico Menonita De Cayey, Edificio Profesional Suite 410, Cayey, PR 00737 Phone: 787-388-9001 Fax: 787-738-2105 | |
Alicia Mendez, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: Carr 14, Edificio Profesional Menonita Suite 207, Cayey, PR 00736 Phone: 787-263-0411 Fax: 787-263-0970 | |
Dr. Mayra Velez Rivera, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Hospital Menonita Cayey Carr 14 Km 72.0 Bo Rincon, Sec Lomas, Cayey, PR 00737 Phone: 787-535-1001 Fax: 787-535-1012 |